Arkolith/Insider Trading/SUPN/Form 4

Khattar Jack A.

President, CEO, DirectorSUPERNUS PHARMACEUTICALS, INC. (SUPN) · full profile →Form 4 · filed Mar 16, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.8M
Net Open-Market Flow
-$1.8M
Transactions
5
5 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 13, 2026Sell(S)120$51.75$6K958K
Mar 13, 2026Sell(S)11K$51.00$548K958K
Mar 13, 2026Other(J)13K——993K
Mar 13, 2026Other(J)13K——1.2M
Mar 13, 2026Sell(S)24K$50.09$1.2M969K

Transaction Codes

S
Open-market sale
J
Other acquisition / disposition

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001539937-26-000008) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML